Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance-Reference-Cited by-同舟云学术

Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance

Published:2013-05-01 Issue:7 Volume:8 Page:1469-1478
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Ali Akbar¹,Aydin Cihan¹,Gildemeister Reinhold¹,Romano Keith P.,Cao Hong¹,Özen Ayşegül¹,Soumana Djade¹,Newton Alicia²,Petropoulos Christos J.²,Huang Wei²,Schiffer Celia A.¹

Affiliation:

1. Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States

2. Monogram Biosciences, South San Francisco, California 94080, United States

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/cb400100g

Reference50 articles.

1. World Health Organization (WHO). Hepatitis C, Fact SheetNo 164 (July 2012). http://www.who.int/mediacentre/factsheets/fs164/en/index.html; accessed February 2013.

2. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

3. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

4. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

5. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance;Viruses;2024-09-05

2. Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease;Viruses;2024-08-03

3. ALK/multikinase Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08

4. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

5. Antiviral drugs and vaccines;Medicinal Chemistry of Chemotherapeutic Agents;2023